Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

被引：0
|
作者：
Lu Si
Xiaoshi Zhang
Zhen Xu
Qiudi Jiang
Lilian Bu
Xuan Wang
Lili Mao
Weijiang Zhang
Nicole Richie
Jun Guo
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Sun Yat-sen University Cancer Center,undefined
[3] Roche Product Development in Asia Pacific,undefined
[4] Roche R&D Center China Ltd.,undefined
[5] Roche Innovation Center New York,undefined
[6] Genentech,undefined
[7] Inc.,undefined
来源：
BMC Cancer | / 18卷
关键词：
-positive; Advanced melanoma; Vemurafenib; China; Asia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
    Larkin, James
    Brown, Michael P.
    Arance, Ana M.
    Hauschild, Axel
    Queirolo, Paola
    Del Vecchio, Michele
    Ascierto, Paolo A.
    Krajsova, Ivana
    Schachter, Jacob
    Neyns, Bart
    Garbe, Claus
    Sileni, Vanna Chiarion
    Mandala, Mario
    Gogas, Helen
    Espinosa, Enrique
    Hospers, Geke
    Lorigan, Paul
    Nyakas, Marta
    Guminski, Alex
    Liszkay, Gabriela
    Rutkowski, Piotr
    Miller, Wilson, Jr.
    Donica, Margarita
    Makrutzki, Martina
    Blank, Christian
    EUROPEAN JOURNAL OF CANCER, 2019, 107 : 175 - 185
  • [32] Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
    McArthur, Grant A.
    Chapman, Paul B.
    Robert, Caroline
    Larkin, James
    Haanen, John B.
    Dummer, Reinhard
    Ribas, Antoni
    Hogg, David
    Hamid, Omid
    Ascierto, Paolo A.
    Garbe, Claus
    Testori, Alessandro
    Maio, Michele
    Lorigan, Paul
    Lebbe, Celeste
    Jouary, Thomas
    Schadendorf, Dirk
    O'Day, Stephen J.
    Kirkwood, John M.
    Eggermont, Alexander M.
    Dreno, Brigitte
    Sosman, Jefferey A.
    Flaherty, Keith T.
    Yin, Ming
    Caro, Ivor
    Cheng, Suzanne
    Trunzer, Kerstin
    Hauschild, Axel
    LANCET ONCOLOGY, 2014, 15 (03): : 323 - 332
  • [33] Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma
    Robert, C.
    Lewis, K. D.
    Gutzmer, R.
    Stroyakovskiy, D.
    Gogas, H.
    Protsenko, S.
    Pereira, R. P.
    Eigentler, T.
    Rutkowski, P.
    Demidov, L.
    Caro, I
    Forbes, H.
    Shah, K.
    Yan, Y.
    Li, H.
    McArthur, G. A.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (05) : 544 - 555
  • [34] Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
    Brose, Marcia S.
    Cabanillas, Maria E.
    Cohen, Ezra E. W.
    Wirth, Lori J.
    Riehl, Todd
    Yue, Huibin
    Sherman, Steven I.
    Sherman, Eric J.
    LANCET ONCOLOGY, 2016, 17 (09): : 1272 - 1282
  • [35] Phase I/II open-label multicenter study of palbociclib in BRAFV600mut metastatic melanoma patients harbouring CDKN2A loss and RB1 expression and treated with vemurafenib (NCT 02202200)
    Louveau, B.
    Resche-Rigon, M.
    Lesimple, T.
    Da Meda, L.
    Pracht, M.
    Baroudjian, B.
    Delyon, J.
    Amini-Adle, M.
    Dutriaux, C.
    De Moura, C. Reger
    Sadoux, A.
    Jouenne, F.
    Ghrieb, Z.
    Vilquin, P.
    Bouton, D.
    Tibi, A.
    Huguet, S.
    Rezai, K.
    Battistella, M.
    Mourah, S.
    Lebbe, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 134 - 134
  • [36] BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma
    Chisholm, Julia C.
    Suvada, Jozef
    Dunkel, Ira J.
    Casanova, Michela
    Zhang, Weijiang
    Ritchie, Natasha
    Choi, YounJeong
    Park, Jane
    Das Thakur, Meghna
    Simko, Stephen
    Tam, Nga Wan Rachel
    Ferrari, Andrea
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
  • [37] Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib
    Schadendorf, Dirk
    Di Giacomo, Anna Maria
    Demidov, Lev
    Merelli, Barbara
    Bondarenko, Igor
    Ascierto, Paolo A.
    Herbert, Christopher
    Mackiewicz, Andrzej
    Rutkowski, Piotr
    Guminski, Alexander
    Goodman, Grant R.
    Simmons, Brian
    Ye, Chenglin
    Hong, Agnes
    Lewis, Karl
    EUROPEAN JOURNAL OF CANCER, 2019, 123 : 155 - 161
  • [38] Vemurafenib in patients with BRAFV600 mutation-positive meta-static melanoma: final overall survival results of the BRIM-3 study
    Chapman, Paul B.
    Robert, Caroline
    Larkin, James
    Haanen, John B.
    Ribas, Antoni
    Hogg, David
    Hamid, Omid
    Ascierto, Paolo Antonio
    Testori, Alessandro
    Lorigan, Paul
    Dummer, Reinhard
    Sosman, Jeffrey A.
    Flaherty, Keith T.
    Yue, Huibin
    Coleman, Shelley
    Caro, Ivor
    Hauschild, Axel
    McArthur, Grant A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [39] Early FDG-PET monitoring of mutated BRAFV600 metastatic melanoma patients undergoing Vemurafenib treatment
    Aloj, L.
    Caraco, C.
    Di Gennaro, F.
    Grimaldi, A. M.
    Simeone, E.
    Romano, A.
    Caraco, C.
    Mozzillo, N.
    Torri, V.
    Ascierto, P. A.
    Lastoria, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S190 - S190
  • [40] AN OPEN-LABEL MULTICENTER PHASE II TRIAL OF AVISCUMINE IN PREVIOUSLY TREATED PATIENTS WITH UNRESECTABLE STAGE IV METASTATIC MELANOMA
    Uwe, Trefzer
    Ralf, Gutzmer
    Tabea, Wilhelm
    Florian, Schenck
    Katharina, Kaehler C.
    Volkmar, Jacobi
    Klaus, Witthohn
    Hans, Lentzen
    Peter, Mohr
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S7 - S7
12345